Elaine Ullian, Director at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 22,500 shares at $130.68 ($2.9M) on 2015-12-01, disclosed to the SEC on 2015-12-03.
Scheduled sale ($2.9M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $128.78 | 6,289 | $810K | 27.7% |
| 2 | $129.77 | 10,711 | $1.4M | 47.6% |
| 3 | $130.68 | 5,400 | $706K | 24.2% |
| 4 | $131.38 | 100 | $13K | 0.5% |
| Total | $129.72 avg | 22,500 | $2.9M | 100% |
| Filing → |
| HOLX | SELL | 2017-07-06 | $801K | — | Filing → |
| HOLX | SELL | 2017-06-06 | $786K | — | Filing → |
| HOLX | SELL | 2017-05-05 | $799K | — | Filing → |